Anti-tuberculosis and cytotoxic evaluation of the seaweed Sargassum boveanum

Vajihe Akbari, Saeed Zafari, Afsaneh Yegdaneh


Marine seaweeds produce a variety of compounds with different biological activities, including anti-tuberculosis and anticancer effects. The aim of this study was to investigate anti-tuberculosis activity of Sargassum boveanum (S. boveanum) and cytotoxicity of different fractions of this seaweed. S. boveanum was collected from Persian Gulf. The plant was extracted by maceration with methanol-ethyl acetate solvent. The extract was evaporated and partitioned by Kupchan method to yield hexane, tricholoroethane, chloroform, and butanol partitions. The anti-tuberculosis activity of the crude extract and toxicity of the fractions were investigated using green fluorescent protein reporter microplate assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay methods, respectively. The cell survivals of HeLa cell were decreased by increasing the concentration of the extracts. The IC50 values of hexane, tricholoroethane, chloroform, and butanol partitions were 150.3 ± 23.10, 437.0 ± 147.3, 110.4 ± 33.67, and 1025.0 ± 15.20 μg/mL, respectively. The crude extract was not active against tuberculosis. This study reveals that different partitions of S. boveanum have cytotoxic activity against the cancer cell lines.


Sargassum; Persian Gulf; Tuberculosis; Cytotoxic

Full Text:



Bodnar KA, Serbina NV, Flynn JN. Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect Immun. 2001;69(2):800-809.

Mitscher LA, Baker W. Tuberculosis: a search for novel therapy starting with natural products. Med Res Rev. 1998;18(6):363-374.

Adhikari PR. Probabilistic Modelling of Multiresolution Biological Data. Department of information and computer science, Aalto university publication series doctoral dissertations 157/2014, Finland. 2014.

Gulland A. Global cancer prevalence is growing at “alarming pace,” says WHO. BMJ. 2014;348:g1338.

Schwartsmann G. Marine organisms and other novel natural sources of new cancer drugs. Ann Oncol. 2000;11(3):235-243.

Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001;2(4):221-225.

Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2013;30(2):237-323.

Yegdaneh A, Putchakarn S, Yuenyongsawad S, Ghannadi A, Plubrukarn A. 3-oxoabolene and 1-oxocurcuphenol, aromatic bisabolanes from the sponge Myrmekioderma sp. Nat prod Commun. 2013;8(10):1355-1357.

Solanki R, Khanna M, Lal R. Bioactive compounds from marine actinomycetes. Indian J Microbiol. 2008;48(4):410-431.

Rinehart KL. Antitumor compounds from tunicates. Med Res Rev. 2000;20(1):1-27.

TÜney İ, Cadirci BH, Ünal D, Sukatar A. Antimicrobial activities of the extracts of marine algae from the coast of Urla (Izmir, Turkey). Turk J Biol. 2006;30(3):171-175.

Yegdaneh A, Ghannadi A, Dayani L. Chemical constituents and biological activities of two Iranian Cystoseira species. Res Pharm Sci. 2016;11(4): 311-317.

Tang HF, Yang-Hua Y, Yao XS, Xu QZ, Zhang SY, Lin HW. Bioactive steroids from the brown alga Sargassum carpophyllum. J Asian Nat Prod Res. 2002;4(2):95-101.

Mehdinezhad N, Ghannadi A, Yegdaneh A. Phytochemical and biological evaluation of some Sargassum species from Persian Gulf. Res Pharm Sci. 2016;11(3):243-249.

Ghannadi A, Plubrukarn A, Zandi K, Sartavi K, Yegdaneh A. Screening for antimalarial and acetylcholinesterase inhibitory activities of some Iranian seaweeds. Res pharm sci. 2013;8(2): 113-118.

Sohrabipour J, Rabiei R. The checklist of green algae of the Iranian coastal lines of the Persian Gulf and Gulf of Oman. Iran J Bot. 2007;13(2):146-149.

Kupchan SM, Tsou G. Tumor inhibitors. structure and partial synthesis of fabacein. J Org Chem. 1973;38(5):1055-1056.

Collins LA, Torrero MN, Franzblau SG. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998;42(2):344-347.

Cooksey RC, Crawford JT, Jacobs WR Jr, Shinnick TM. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother. 1993;37(6):1348-1352.

Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother. 1997;41(5):1004-1009.

Akbari V, Abedi D, Pardakhty A, Sadeghi-Aliabadi H. Ciprofloxacin nano-niosomes for targeting intracellular infections: an in vitro evaluation. J Nanopart Res. 2013;15(4):1-14.

Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis. 1988;137(5):1217-1222.

Changsen C, Franzblau SG, Palittapongarnpim P. Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrob Agents Chemother. 2003;47(12):3682-3687.

Mary JS, Vinotha P, Pradeep AM. Screening for in vitro cytotoxic activity of seaweed, Sargassum sp. against Hep-2 and MCF-7 cancer cell lines. Asian Pac J Cancer Prev. 2012;13(12):6073-6076.

Tannourya MY, Eliaa JM, Saabc AM, Makhloufb HY, Abboudd JS, Daou-Chaboa RJ, et al. Evaluation of cytotoxic activity of Sargassum vulgare From the Lebanese Coast against Jurkat cancer cell line. J App Pharm Sci. 2016;6(6): 108-112.

Khanavi M, Nabavi M, Sadati N, Shams Ardekani M, Sohrabipour J, Nabavi SM, et al. Cytotoxic activity of some marine brown algae against cancer cell lines. Biol Res. 2010;43(1):31-37.

Koch A, Tamez P, Pezzuto J, Soejarto D. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J Ethnopharmacol. 2005; 101(1-3):95-99.

Tantengco OAG, Limbo C, Montaño MN, Jacinto S. Cytotoxic activity of crude extract and fractions from Sargassum siliquosum (JG Agardh) and other seaweeds against selected human cancer cell lines. Int J Biosci (IJB). 2015;7(2):207-215.

Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, et al. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science. 1998;280(5369):1607-1610.

Snell NJ. The treatment of tuberculosis: current status and future prospects. Expert opin Investig Drugs. 1998;7(4):545-552.

Rouhi AM. Tuberculosis: a tough adversary-With the tools for a renewed battle in place, development of new weapons to combat the ancient plague should proceed at a rapid pace. Chem Eng News. 1999;77(20):52-64.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.